New facts about encapsulating peritoneal sclerosis as a sequel of long-term peritoneal dialysis - What can we do?

Minerva Urologica e Nefrologica

Volumn 59, Issue 3, 2007, Pages 269-279

  Alscher, D M ^a   Reimold, F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Fibrosis; Mast cells; Peritoneal dialysis; Sclerosis; Vascular Endothelial Growth Factor A

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BEVACIZUMAB; CHYMASE; FIBRIN; GLUCOCORTICOID; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; PLASMIN; STEROID; TAMOXIFEN; TRYPTASE; VASCULOTROPIN;

ABDOMINAL RADIOGRAPHY; ABDOMINAL SURGERY; ANGIOGENESIS; CANCER; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ENCAPSULATING PERITONEAL SCLEROSIS; FIBROBLAST; HUMAN; INTESTINE OBSTRUCTION; LABORATORY TEST; LONG TERM CARE; MALNUTRITION; MAST CELL; MORTALITY; PARENTERAL NUTRITION; PATHOGENESIS; PATIENT MONITORING; PERITONEAL BIOPSY; PERITONEAL DIALYSIS; PERITONEUM LAVAGE; RETROPERITONEAL FIBROSIS; REVIEW; SCLEROSIS; STAGING;

HUMANS; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; SCLEROSIS; TIME FACTORS;

EID: 36749095690     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Blake PG. Peritoneal dialysis in the USA. Perit Dial Int 2006;26:416-8.
2. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. QuaSI-Niere Jahresbericht 2006;2005/2006:14-28.
3. Mehrotra R. Peritoneal dialysis penetration in the United States: march toward the fringes? Perit Dial Int 2006;26:419-22.
4. Schleifer CR. The sun is setting on peritoneal dialysis and no new stars are rising. Perit Dial Int 2007;27:311.
5. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000;11:116-25.
6. Nakamoto H, Kawaguchi Y, Suzuki H. Is technique survival on peritoneal dialysis better in Japan? Perit Dial Int 2006;26:136-43.
7. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005;25(Suppl 4):S14-8.
8. Nakamoto H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005;25(Suppl 4):S30-8.
9. Krediet RT. Advances in peritoneal dialysis: towards improved efficacy and safety. Blood Purif 1998;16:1-14.
10. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002;18:131-4.
11. Alscher DM, Braun N, Biegger D, Fritz P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007;49:452-61.
12. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996;28:420-7.
13. Alscher DM, Mettang T. Procalcitonin in peritoneal dialysis-a useful marker of inflammation? Perit Dial Int 2005;25:441-4.
14. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis 1994;24:819-25.
15. Korzets A, Korzets Z, Peer G, Papo J, Stern D, Bernheim J et al. Sclerosing peritonitis. Possible early diagnosis by computerized tomography of the abdomen. Am J Nephrol 1988;8:143-6.
16. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005;25(Suppl 4):S83-95.
17. Hollman AS, McMillan MA, Briggs JD, Junor BJ, Morley P. Ultrasound changes in sclerosing peritonitis following continuous ambulatory peritoneal dialysis. Clin Radiol 1991;43:176-9.
18. Verbanck JJ, Schoonjans RS, Vandewiele IA, Segaert MF, Crolla DP, Tanghe WR. Sclerosing peritonitis with gross peritoneal calcification and abdominal wall abscess secondary to bowel perforation: ultrasonographic appearance. J Clin Ultrasound 1997;25:136-40.
19. Hare CM. Radiological view of sclerosing peritonitis. Nephrol Dial Transplant 1999;14:497-8.
20. Winnen P. Über Zuckergussdarm (peritonitis chronica fibrosa incapsulata). Brunns Beitr Klin Chir 1921;123:72.
21. Narayanan R, Bhargava BN, Kabra SG, Sangal BC. Idiopathic sclerosing encapsulating peritonitis. Lancet 1989;2:127-9.
22. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004;44:729-37.
23. Topley N. Encapsulating peritoneal sclerosis: time to act. Perit Dial Int 2006;26:564-5.
24. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-9.
25. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006;17:199-207.
26. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999;14:1541-9.
27. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005;67:1559-65.
28. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358-73.
29. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(Suppl 4):S19-29.
30. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58.
31. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:1927-36.
32. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000;11:717-28.
33. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-26.
34. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
35. Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001;12:1668-76.
36. Bird SD, Walker RJ. Mast cell histamine-induced calcium transients in cultured human peritoneal mesothelial cells. Perit Dial Int 1998;18:626-36.
37. Qu Z, Kayton RJ, Ahmadi P, Liebler JM, Powers MR, Planck SR et al. Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules. Morphological evidence for bfgf release through degranulation. J Histochem Cytochem 1998;46:1119-28.
38. Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang XN et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995;147:564-73.
39. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 1998;9:875-84.
40. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997;99:2691-700.
41. Muramatsu M, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000;275:5545-52.
42. Nakayama M. The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int 2005;25(Suppl 4):S71-6.
43. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
44. Schwartz LB, Bradford TR, Littman BH, Wintroub BU. The fibrinogenolytic activity of purified tryptase from human lung mast cells. J Immunol 1985;135:2762-7.
45. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
46. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
47. Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis 2006;47:697-712.
48. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005;25:248-55.
49. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000;20(Suppl 4):S43-55.
50. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998;13:154-9.
51. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988;3:66-9.
52. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987;57:239-47.
53. Kawaguchi Y, Hasegawa T, Kubo H, Yamamoto H, Nakayama M, Shigematsu T. Current issues of continuous ambulatory peritoneal dialysis. Artif Organs 1995;19:1204-9.
54. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Shishida M et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002;18:149-53.
55. Rodrigues A, Cabrita A, Maia P, Guimaraes S. Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002;18:78-80.
56. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis -Jikei experience 2002. Adv Perit Dial 2002;18:144-8.
57. Kawanishi H, Harada Y, Sakikubo E, Moriishi M, Nagai T, Tsuchiya S. Surgical treatment for sclerosing encapsulating peritonitis. Adv Perit Dial 2000;16:252-6.
58. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997;30:275-8.
59. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004;19:2423-4.
60. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003;19:32-5.
61. Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999;12:395-7.
62. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, Moriishi M et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001;17:200-4.
63. Yamamoto H, Nakayama M, yamamoto R, Otsuka Y, Takahashi H, Kato N et al. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 2002;18:135-8.